Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in 2023

Read more at globenewswire.com